Selected research
Industry Research
Antisense and RNAi Therapeutics Drug Industry Research Report 2026
Market perspective
The global Antisense and RNAi Therapeutics Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Antisense and RNAi Therapeutics Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Antisense and RNAi Therapeutics Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Antisense and RNAi Therapeutics Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Antisense and RNAi Therapeutics Drug include Biogen, Sarepta Therapeutics, Kastle therapeutics, Jazz Pharmaceuticals, Dynavax Technologies, Bausch & Lomb, Alnylam Pharmaceuticals and Akcea Therapeutics, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Antisense and RNAi Therapeutics Drug market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Antisense and RNAi Therapeutics Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Antisense and RNAi Therapeutics Drug Market by Company
Biogen
Sarepta Therapeutics
Kastle therapeutics
Jazz Pharmaceuticals
Dynavax Technologies
Bausch & Lomb
Alnylam Pharmaceuticals
Akcea Therapeutics
Antisense and RNAi Therapeutics Drug Segment by Type
Antisense Oligonucleotide
Aptamer
Other
Antisense and RNAi Therapeutics Drug Segment by Application
ATTR
Hepatic VOD
Neuromuscular Diseases
Other
Antisense and RNAi Therapeutics Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antisense and RNAi Therapeutics Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antisense and RNAi Therapeutics Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antisense and RNAi Therapeutics Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Antisense and RNAi Therapeutics Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Antisense Oligonucleotide
- Aptamer
- Other
Applications
- ATTR
- Hepatic VOD
- Neuromuscular Diseases
- Other
Companies covered
- Biogen
- Sarepta Therapeutics
- Kastle therapeutics
- Jazz Pharmaceuticals
- Dynavax Technologies
- Bausch & Lomb
- Alnylam Pharmaceuticals
- Akcea Therapeutics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Antisense and RNAi Therapeutics Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Antisense Oligonucleotide
- 2.2.3 Aptamer
- 2.2.4 Other
- 2.3 Antisense and RNAi Therapeutics Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 ATTR
- 2.3.3 Hepatic VOD
- 2.3.4 Neuromuscular Diseases
- 2.3.5 Other
- 2.4 Assumptions and Limitations
3 Antisense and RNAi Therapeutics Drug Breakdown Data by Type
- 3.1 Global Antisense and RNAi Therapeutics Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Antisense and RNAi Therapeutics Drug Forecasted Market Size by Type (2027-2032)
4 Antisense and RNAi Therapeutics Drug Breakdown Data by Application
- 4.1 Global Antisense and RNAi Therapeutics Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Antisense and RNAi Therapeutics Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Antisense and RNAi Therapeutics Drug Market Perspective (2021-2032)
- 5.2 Global Antisense and RNAi Therapeutics Drug Growth Trends by Region
- 5.2.1 Global Antisense and RNAi Therapeutics Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Antisense and RNAi Therapeutics Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Antisense and RNAi Therapeutics Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Antisense and RNAi Therapeutics Drug Market Dynamics
- 5.3.1 Antisense and RNAi Therapeutics Drug Industry Trends
- 5.3.2 Antisense and RNAi Therapeutics Drug Market Drivers
- 5.3.3 Antisense and RNAi Therapeutics Drug Market Challenges
- 5.3.4 Antisense and RNAi Therapeutics Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Antisense and RNAi Therapeutics Drug Players by Revenue
- 6.1.1 Global Top Antisense and RNAi Therapeutics Drug Players by Revenue (2021-2026)
- 6.1.2 Global Antisense and RNAi Therapeutics Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Antisense and RNAi Therapeutics Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Antisense and RNAi Therapeutics Drug Head Office and Area Served
- 6.4 Global Antisense and RNAi Therapeutics Drug Players, Product Type & Application
- 6.5 Global Antisense and RNAi Therapeutics Drug Manufacturers Established Date
- 6.6 Global Antisense and RNAi Therapeutics Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Antisense and RNAi Therapeutics Drug Market Size (2021-2032)
- 7.2 North America Antisense and RNAi Therapeutics Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Antisense and RNAi Therapeutics Drug Market Size by Country (2021-2026)
- 7.4 North America Antisense and RNAi Therapeutics Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Antisense and RNAi Therapeutics Drug Market Size (2021-2032)
- 8.2 Europe Antisense and RNAi Therapeutics Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Antisense and RNAi Therapeutics Drug Market Size by Country (2021-2026)
- 8.4 Europe Antisense and RNAi Therapeutics Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Antisense and RNAi Therapeutics Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Antisense and RNAi Therapeutics Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Antisense and RNAi Therapeutics Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Antisense and RNAi Therapeutics Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Antisense and RNAi Therapeutics Drug Market Size (2021-2032)
- 10.2 South America Antisense and RNAi Therapeutics Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Antisense and RNAi Therapeutics Drug Market Size by Country (2021-2026)
- 10.4 South America Antisense and RNAi Therapeutics Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Antisense and RNAi Therapeutics Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Antisense and RNAi Therapeutics Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Antisense and RNAi Therapeutics Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Antisense and RNAi Therapeutics Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Biogen
- 12.1.1 Biogen Company Information
- 12.1.2 Biogen Business Overview
- 12.1.3 Biogen Revenue in Antisense and RNAi Therapeutics Drug Business (2021-2026)
- 12.1.4 Biogen Antisense and RNAi Therapeutics Drug Product Portfolio
- 12.1.5 Biogen Recent Developments
- 12.2 Sarepta Therapeutics
- 12.2.1 Sarepta Therapeutics Company Information
- 12.2.2 Sarepta Therapeutics Business Overview
- 12.2.3 Sarepta Therapeutics Revenue in Antisense and RNAi Therapeutics Drug Business (2021-2026)
- 12.2.4 Sarepta Therapeutics Antisense and RNAi Therapeutics Drug Product Portfolio
- 12.2.5 Sarepta Therapeutics Recent Developments
- 12.3 Kastle therapeutics
- 12.3.1 Kastle therapeutics Company Information
- 12.3.2 Kastle therapeutics Business Overview
- 12.3.3 Kastle therapeutics Revenue in Antisense and RNAi Therapeutics Drug Business (2021-2026)
- 12.3.4 Kastle therapeutics Antisense and RNAi Therapeutics Drug Product Portfolio
- 12.3.5 Kastle therapeutics Recent Developments
- 12.4 Jazz Pharmaceuticals
- 12.4.1 Jazz Pharmaceuticals Company Information
- 12.4.2 Jazz Pharmaceuticals Business Overview
- 12.4.3 Jazz Pharmaceuticals Revenue in Antisense and RNAi Therapeutics Drug Business (2021-2026)
- 12.4.4 Jazz Pharmaceuticals Antisense and RNAi Therapeutics Drug Product Portfolio
- 12.4.5 Jazz Pharmaceuticals Recent Developments
- 12.5 Dynavax Technologies
- 12.5.1 Dynavax Technologies Company Information
- 12.5.2 Dynavax Technologies Business Overview
- 12.5.3 Dynavax Technologies Revenue in Antisense and RNAi Therapeutics Drug Business (2021-2026)
- 12.5.4 Dynavax Technologies Antisense and RNAi Therapeutics Drug Product Portfolio
- 12.5.5 Dynavax Technologies Recent Developments
- 12.6 Bausch & Lomb
- 12.6.1 Bausch & Lomb Company Information
- 12.6.2 Bausch & Lomb Business Overview
- 12.6.3 Bausch & Lomb Revenue in Antisense and RNAi Therapeutics Drug Business (2021-2026)
- 12.6.4 Bausch & Lomb Antisense and RNAi Therapeutics Drug Product Portfolio
- 12.6.5 Bausch & Lomb Recent Developments
- 12.7 Alnylam Pharmaceuticals
- 12.7.1 Alnylam Pharmaceuticals Company Information
- 12.7.2 Alnylam Pharmaceuticals Business Overview
- 12.7.3 Alnylam Pharmaceuticals Revenue in Antisense and RNAi Therapeutics Drug Business (2021-2026)
- 12.7.4 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Drug Product Portfolio
- 12.7.5 Alnylam Pharmaceuticals Recent Developments
- 12.8 Akcea Therapeutics
- 12.8.1 Akcea Therapeutics Company Information
- 12.8.2 Akcea Therapeutics Business Overview
- 12.8.3 Akcea Therapeutics Revenue in Antisense and RNAi Therapeutics Drug Business (2021-2026)
- 12.8.4 Akcea Therapeutics Antisense and RNAi Therapeutics Drug Product Portfolio
- 12.8.5 Akcea Therapeutics Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst